article Open AccessTop 10% cited
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Breast Cancer Research and Treatment · 2008 · Vol. 116(1) · pp. 53–68
Robin L. Jones✉(Royal Marsden Hospital)Janine Salter(Royal Marsden NHS Foundation Trust)Roger A’Hern(Institute of Cancer Research)A Nerurkar(Royal Marsden Hospital)Marina Parton(Royal Marsden Hospital)Jorge S. Reis‐Filho(Institute of Cancer Research)Ian E. Smith(Royal Marsden Hospital)Mitch Dowsett(Royal Marsden Hospital)
Breast Cancer Treatment StudiesBreast Lesions and CarcinomasCancer Cells and MetastasisMedicineBreast cancerChemotherapyOncologyInternal medicineMultivariate analysisPathologicalNeoadjuvant therapyRadiation therapyRegimen
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesBiomarkers, TumorRadiotherapy, AdjuvantKi-67 Antigen
Citations
324
FWCI
11.26
field-weighted impact
References
23
Percentile
98%
vs. same field & year
Citations per year
Cited by
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
PLoS Medicine · 2012 · 1,021 citations
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
JNCI Journal of the National Cancer Institute · 2011 · 1,975 citations
References
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
British Journal of Cancer · 2007 · 954 citations
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
The Journal of Immunology · 1984 · 4,197 citations
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
JNCI Journal of the National Cancer Institute · 2008 · 1,789 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.